about
Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapyUtility of blood procalcitonin concentration in the management of cancer patients with infectionsSphingosine-1-Phosphate Metabolism and Its Role in the Development of Inflammatory Bowel DiseaseReal-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37.Compression stiffening of brain and its effect on mechanosensing by glioma cellsBactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juiceGold-functionalized magnetic nanoparticles restrict growth of Pseudomonas aeruginosa.Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosisFormulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13.Novel cationic lipids with enhanced gene delivery and antimicrobial activity.Plasma gelsolin modulates cellular response to sphingosine 1-phosphate.Increased levels of sphingosine-1-phosphate in cerebrospinal fluid of patients diagnosed with tick-borne encephalitisSalmon and human thrombin differentially regulate radicular pain, glial-induced inflammation and spinal neuronal excitability through protease-activated receptor-1Polyelectrolyte-mediated increase of biofilm mass formation.Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles.Synthesis and structure-activity relationships of novel cationic lipids with anti-inflammatory and antimicrobial activities.Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cellsBactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection.The Role of Cathelicidin LL-37 in Cancer Development.Plasma gelsolin: function, prognostic value, and potential therapeutic use.Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.Core-shell magnetic nanoparticles display synergistic antibacterial effects against Pseudomonas aeruginosa and Staphylococcus aureus when combined with cathelicidin LL-37 or selected ceragenins.Augmentation of integrin-mediated mechanotransduction by hyaluronic acid.Sporicidal activity of ceragenin CSA-13 against Bacillus subtilis.Development of antifungal therapies using nanomaterials.Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo.The search for new sporicidal agents for medical use: where are we?Cathelicidin LL-37 increases lung epithelial cell stiffness, decreases transepithelial permeability, and prevents epithelial invasion by Pseudomonas aeruginosa.Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.Inactivation of endotoxin by human plasma gelsolin.The synthesis and antifungal activity of (20S)-3β-acetoxy-5α-pregnane-20,16β-carbolactone against fluconazole - Resistant Candida cells.Magnetic nanoparticles as a drug delivery system that enhance fungicidal activity of polyene antibiotics.Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate.Application of multiplexing technology to the analysis of the intrathecally released immunoglobulins against B. burgdorferi antigens in neuroborreliosis.Growth arrest and rapid capture of select pathogens following magnetic nanoparticle treatment.Enhancement of Pulmozyme activity in purulent sputum by combination with poly-aspartic acid or gelsolin.Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections.Change in blood gelsolin concentration in response to physical exercise.
P50
Q26745710-23B6D2E9-3C56-4AB7-8221-802B7F101AACQ26768122-89B7D0F8-D9D9-46C7-AA2B-D498438DEBEEQ30235011-2C0C861D-9608-4BCB-B5C0-678ADC2AF3BCQ30499787-C98A5EF4-2116-4257-ABC8-F751D14BBA5DQ30634187-C921D7B0-B0DC-4A20-A8A2-4DD1798C3D05Q33499892-F06D3568-CA26-4412-BB1C-8A0EC7229103Q33610519-FCCA5E2B-FDD1-4BAF-92E9-8AAA4E35B833Q33735371-67F3329E-7538-48A2-8CAB-F6419547849DQ33870762-8331F926-ADD7-4713-9295-6CC95C9D5994Q34127970-22086638-5523-41C9-B68A-CD71D38BA79BQ34426423-A85F6035-F90D-40A6-B66E-7F4E1BFD869AQ34645463-CEFF3DB9-C52C-496F-B4E9-4E3C652C31B8Q35053403-1A88B698-3406-4D70-9043-5F3733F8385EQ35654991-A26DA3A5-0C85-46BE-BA7F-F74BF3F5860DQ35689986-7401C2AF-C862-4A84-8FDD-AEAD9EB2E7D8Q35695892-AED40AE4-3938-49B0-BC01-FFAE9B8F956AQ35703756-4916ADFE-99EA-46D8-AB8C-503B2EB6934DQ35746038-740073DF-0611-4444-B131-ED468FB3C8CCQ36055572-EAFFDE88-CB12-4D9C-B142-B337735B837DQ36076086-6609B500-51EF-4E81-BF42-E60ADD56F4BFQ36465085-CB8DF6B0-ECBA-4D12-89E6-3B01082C1C05Q37347466-B8254CC4-018B-47E5-9955-2F414CEC9978Q37349847-8ADDC8DD-129B-401E-8DF7-EC44B8EE4431Q37361845-7B2268A3-8C72-4D94-839B-5D2AE472D9E3Q37595529-5689EA8D-DEB4-4C4D-9764-821621A281E3Q37704569-B4BDFA3C-4068-41CC-A67F-93EFCEFDB11EQ38658275-C036326A-6C92-4A3C-851F-3B121D3317AFQ38659649-CB2F8DA5-F864-4BED-8DB7-CA5776292D6FQ38673389-5DA62836-9DF6-4157-9FFE-C5A88E83B533Q39440971-8AE79268-6726-4787-98C4-1A36F22BC0ABQ40160132-7D0807A8-C38B-4E61-BD13-7CCE64CD0A97Q40399230-5ED46D70-2E6E-40AC-BF0C-430470D3EEB5Q40401855-55C1F08F-BB0F-4129-8F38-862D52ACBB15Q40597714-CA43065E-9ACD-4704-8802-1A4CF543592DQ40749497-40F153A3-4B8E-47A5-A570-E4F5A123D6FCQ41090189-4F865485-2E32-49DB-8DAF-FD1B31D80593Q41258372-C9454D43-CD57-4E7E-813D-FA043EFC2630Q41483008-61B6CC6F-8BBF-4E8E-875B-A975054B4E94Q41981409-AFF46146-EB8E-4FE9-8209-A969CEBEF392Q42003996-C2154FED-3E64-49EF-A012-6569410B1054
P50
description
researcher ORCID ID = 0000-0001-7664-9226
@en
wetenschapper
@nl
name
Robert Bucki
@ast
Robert Bucki
@en
Robert Bucki
@es
Robert Bucki
@nl
Robert Bucki
@pl
type
label
Robert Bucki
@ast
Robert Bucki
@en
Robert Bucki
@es
Robert Bucki
@nl
Robert Bucki
@pl
prefLabel
Robert Bucki
@ast
Robert Bucki
@en
Robert Bucki
@es
Robert Bucki
@nl
Robert Bucki
@pl
P106
P1153
6701383359
P31
P496
0000-0001-7664-9226